Outlook Q1: GAAP EPS $0.72 (fair value gains), adj EPS -$0.89; BLA resubmission on track

Outlook Therapeutics, Inc.

2025-Q1 EPS reported $0.72

GAAP net income $17.4M ($0.72/sh) vs net loss $11.2M; adj net loss $21.6M ($0.89/sh) vs $10.1M ($0.78 loss) prior year.
BLA resubmission for ONS-5010 (bevacizumab-vikg) targeted for Q1 CY2025; potential FDA approval in Q3 CY2025.
First commercial launches of LYTENAVA in Germany and UK planned for Q2 CY2025; collaboration with Cencora announced.
NORSE EIGHT trial missed primary non-inferiority endpoint at week 8; 12-week analysis met non-inferiority margin.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.